Epithelial Ovarian Cancer Drugs and Companies Pipeline Review H1 2015
Latest report, "Epithelial Ovarian Cancer - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects.
View full press release